The United States and United Kingdom Conclude No-Tariff Accord on Drugs.
The UK and US have secured a key trade agreement that will guarantee no tariffs on British pharmaceutical shipments being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase spending on drugs through the National Health Service (NHS). This move secures that import taxes on these key exports will stay at nothing for a duration of the next three years.
This agreement follows previous threats to hike duties on patented drug products, with increases mentioned as high as 100%.
"This deal between the UK strengthens the global environment for cutting-edge drugs and introduces long-overdue fairness to transatlantic medicine commerce," a statement said.
Economic Impact
Medicines constitute one of the UK's largest goods shipped to the US, which is easily the biggest buyer for major UK drugmakers.
Trade data show that in the 12 months prior to September, the UK sold drugs worth over eleven billion pounds to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal secures work, boosts funding and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed UK Commitments
The deal entails several key commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must pay back to the NHS to stay within budget will be capped at 15%. In the past, refunds topped twenty percent.
Recent Tensions
The deal takes place against a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were exacerbated by arguments that US customers were paying significantly more for the equivalent treatments than people in the other developed nations.
Recently, several major drug company projects in the UK have been paused or scrapped, while major investments have been directed toward US facilities.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a share of its resources over the past decade.
